1. The Pharmaceutical Industry and International Clinical Research: One Company’s Approach Michael Clayman, M.D. Vice President, Lilly Research Laboratories Eli Lilly and Company OIA Speaker Series May 5, 2006

2. OIA Speaker Series May 5, 2005 2 Background Lilly conducts corporate-sponsored clinical research in 17 countries Including India and China With the exception of South Africa, not in Africa Conduct of clinical trials in developing countries considered by Lilly Bioethics Committee (BEC) over several months BEC – R and D leaders (medical, regulatory, legal) + Bob Levine and Tom Beauchamp Consultation with Eric Meslin

3. OIA Speaker Series May 5, 2005 3 Conduct of International Clinical Trials: BEC Position Statement Lilly applies a single baseline global standard to the conduct of clinical trials. Specifically, Lilly conducts all trials in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Clinical Practices and applicable laws and regulations of the country or countries where the study is being conducted.

4. OIA Speaker Series May 5, 2005 4 Conduct of International Clinical Trials: BEC Position Statement Lilly is a global company serving the medical needs of a global population. In choosing locations throughout the world to conduct clinical trials, Lilly is guided by the local prevalence of the burden of disease under study and the medical research capabilities of the candidate institutions.

5. OIA Speaker Series May 5, 2005 5 Conduct of International Clinical Trials: BEC Position Statement In addition, Lilly works in consultation with local ethics committees and/or health authorities, as appropriate, to ensure that conducting the proposed research in each location is scientifically and ethically justified, taking into consideration the following: the risks and benefits for research participants, the potential for the research to yield important scientific advances, the relevance of the research to local health needs and priorities, and the availability of the intervention under study to research participants and/or the community.

6. OIA Speaker Series May 5, 2005 6 Conduct of International Clinical Trials: BEC Position Statement In applying these considerations, Lilly places paramount importance on the safety and well-being of the individual research participants.